APRE Stock Summary and Trading Ideas (Aprea Therapeutics | NASDAQ:APRE)

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.

As of April 18, 2024, APRE stock price was flat at $5.73 with 160 million shares trading.

APRE has a beta of 1.81, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.09 to the broad based SPY ETF.

APRE has a market cap of $31.12 million. This is considered a Sub-Micro Cap stock.

Last quarter Aprea Therapeutics reported $14,075 in Revenue and -$.92 earnings per share. This fell short of revenue expectation by $-95,925 and missed earnings estimates by -$.15.

In the last 3 years, APRE stock traded as high as $156.00 and as low as $.47.

The top ETF exchange traded funds that APRE belongs to (by Net Assets): VTI, VXF, DFSU, DFAC.

APRE has outperformed the market in the last year with a return of +41.5%, while the SPY ETF gained +23.0%. In the last 3 month period, APRE beat the market returning +9.6%, while SPY returned +6.7%. However, in the most recent 2 weeks APRE has underperformed the stock market by returning -14.1%, while SPY returned -3.2%.

APRE support price is $5.30 and resistance is $6.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE stock will trade within this expected range on the day.